# BiSiChem

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bisichem

- Industry: Biotechnology
- Headquarters: Seongnam, South Korea
- Website: www.bisichem.com
- Total disclosed funding: $8.8M
- Latest round: Series B (Apr 15, 2019)
- Investors on record: 3

## About

Based in Seongnam, South Korea, and founded in 2017, BiSiChem is a biotechnology company that focuses on the research and development of novel drugs for various therapeutical areas. The company was co-founded by Jeong-beop Seo (CEO), and Charlie Han (CSO), and in March 2018, BiSiChem raised venture funding from new investor Yozma Group Korea. The company has facilities in Pangyo and Yongin.

BiSiChem primarily discovers and develops novel therapies for the treatment of cancer. Additionally, the company engages in the research of therapeutics for various neurodegenerative conditions including Alzheimer’s and Parkinson’s disease, and furthermore creates targeted drugs for medical conditions such as fibrosis. As of May 2022, the company’s products are in the pre-clinical stage only.

## Funding rounds

- Series B, Apr 15, 2019, $8.8M — KB Securities, Soo Investment Capital, DS Asset Management

## Investors

- KB Securities (https://capitalatlas.ai/funds/kb-securities) — Series B
- Soo Investment Capital (https://capitalatlas.ai/funds/soo-investment-capital) — Series B
- DS Asset Management (https://capitalatlas.ai/funds/ds-asset-management) — Series B